文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

伴与不伴胃食管反流的巴雷特食管及食管腺癌患病率:系统综述与Meta分析

Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-10-24

该系统综述与Meta分析纳入43篇文章(GERD患者12,883例,无GERD者51,350例),比较伴与不伴胃食管反流病(GERD)人群中巴雷特食管(BE)和食管腺癌(EAC)的患病率。无GERD者BE患病率为2.2%,EAC为0.1%;在有GERD者中分别为7%和0.6%。在9项高质量人群研究中,无GERD者BE患病率为4.9%。

要点

  • 无GERD人群BE患病率为2.2%,EAC为0.1%,提示相当比例BE/EAC患者无GERD症状。
  • GERD患者BE风险较高(OR 2.91),长段BE风险更高(OR 4.17),短段BE风险无显著差异。
  • 9项高质量人群研究中无GERD者BE患病率达4.9%,北美研究BE患病率最高。

核心结论

  • 无GERD人群中BE患病率相当可观,尤其在大样本高质量人群研究中。
  • 这些数据对未来BE/EAC早期检测指南的制定具有重要参考价值。

研究设计与样本

  • 系统综述与Meta分析,通过5个主要数据库系统检索报告伴与不伴GERD患者中BE/EAC患病率的研究。
  • 最终纳入43篇文章,包含GERD患者12,883例和无GERD者51,350例。
  • 合并计算BE、长段BE、短段BE、异型增生和EAC的患病比例及比值比(OR)。

主要发现

  • BE患病率在GERD患者中为7%(95%CI 5.8%-8.5%),在无GERD者中为2.2%(95%CI 1.6%-3%)。
  • EAC患病率在GERD患者中为0.6%(95%CI 0.4%-1%),在无GERD者中为0.1%(95%CI 0%-0.2%)。
  • GERD患者BE风险较高(OR 2.91;95%CI 2.06-4.11),长段BE风险亦较高(OR 4.17;95%CI 1.78-9.77)。
  • 短段BE风险在两组间无显著差异(OR 1.77;95%CI 0.89-3.52)。
  • 在9项高质量人群研究中(GERD患者2,244例,无GERD者3,724例),无GERD者BE患病率为4.9%(95%CI 2.6%-9%)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although gastroesophageal reflux disease (GERD) symptoms are an essential criterion for Barrett's esophagus (BE) screening in most gastroenterology society guidelines, a significant proportion of BE and esophageal adenocarcinoma (EAC) cases do not endorse them. In a systematic review and meta-analysis, we aimed to study the prevalence of BE/EAC in those with and without GERD. METHODS: A systematic search was conducted through 5 major databases for studies reporting prevalence of BE/EAC in patients with and without GERD. Pooled proportions and odds ratios (ORs) of BE, long-segment BE, short-segment BE, dysplasia, and EAC in patients with and without GERD were synthesized. RESULTS: Forty-three articles (12,883 patients with GERD; 51,350 patients without GERD) were included in the final analysis. BE prevalence was 7% (95% confidence interval [CI], 5.8%-8.5%) and 2.2% (95% CI, 1.6%-3%) among individuals with and without GERD, respectively. EAC prevalence was 0.6% (95% CI, 0.4%-1%) and 0.1% (95% CI, 0%-0.2%) in those with and without GERD, respectively. The overall risks for BE (OR, 2.91; 95% CI, 2.06-4.11) and long-segment BE (OR,4.17; 95% CI, 1.78-9.77) were higher in patients with GERD, but the risk for short-segment BE (OR, 1.77; 95% CI, 0.89-3.52) did not differ between the two groups. In 9 population-based high-quality studies (2244 patients with GERD; 3724 patients without GERD), BE prevalence in patients without GERD was 4.9% (95% CI, 2.6%-9%). BE prevalence was highest in North American studies (10.6% [GERD] and 4.8% [non-GERD]). CONCLUSIONS: BE prevalence in those without GERD is substantial, particularly in large high-quality population-based studies. These data are important to factor in future BE/EAC early detection guidelines.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Saha B, Vantanasiri K, Mohan BP, et al. Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023. PMID: 37879525. doi:10.1016/j.cgh.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。